P2C 9144: A Phase II Study of Bevacizumab Alone or in Combination with TRC105 for Advanced Renal Cell Cancer
This is a clinical trial of Bevacizumab that will be administered by IV, which is standard of care and TAK105 that will be administered by IV, and is investigational.
IRB Protocol #
MICHAEL WACKER at (720)848-3427 or MICHAEL.WACKER@UCDENVER.EDU
University of Colorado Hospital University of Colorado Hospital
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last up to 1 year. A follow up period will consist of a follow-up exam at least once to make sure any side effects have resolved. // Eligibility criteria include but are not limited to 18 years or older with advanced renal cell cancer.Eligibility criteria include but are not limited to 18 years or older with advanced renal cell cancer.